vTv Therapeutics rises on patent for brain tumor treatment

vTv Therapeutics

24/05/2023 14:59

** Shares of drug developer vTv Therapeutics Inc  VTVT.O 
rise 3.9% to $0.91
    ** Co said a patent was issued to its partner Cantex
Pharmaceuticals Inc for a potential brain tumor treatment
    ** Patent covers claims related to the use of azeliragon as
a potential treatment of glioblastoma multiforme
    ** In June 2021, co and Cantex entered into a licensing
agreement under which Cantex obtained exclusive worldwide rights
to develop and commercialize azeliragon
    ** Stock up ~35% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))